CN1122241A - Naomaitong injection for cerebral angiopathy - Google Patents
Naomaitong injection for cerebral angiopathy Download PDFInfo
- Publication number
- CN1122241A CN1122241A CN 95109431 CN95109431A CN1122241A CN 1122241 A CN1122241 A CN 1122241A CN 95109431 CN95109431 CN 95109431 CN 95109431 A CN95109431 A CN 95109431A CN 1122241 A CN1122241 A CN 1122241A
- Authority
- CN
- China
- Prior art keywords
- injection
- coenzyme
- naomaitong
- citicoline
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
Naomaitong injection consists of red sage 100-300 portions, Vinourutoni 5-15 portions, cytidine diphosphocholine 5-10 portions, coenzyme A 1-2 portions, adenosine triphosphate 0.4 portions and water 240-770 portions. The said medicine has the function of retarding clotting of red blood cell and thrombocyte, can prevent and cure thrombosis, encephaledema and senile dementia, promote angiogenesis and prevent radioactive ray injury and inflammation. It is used via either arteria carotis injection or phleboclysis.
Description
The present invention relates to medicine, is a kind of compound recipe water formulation for the treatment of brain arteries and veins angiopathy.
At present, in treatment brain swift pulse disease, the medicine that uses mostly is that curative effect is low, treatment cycle is long, poison is paid effect greatly, even the meeting that has disables, and do not find a kind of treatment cerebral thrombosis acute stage, the new medicine of comprehensive therapeutic effects such as chronic sequela, apoplexy sequela and thromboangiitis obliterans, superficial phlebitis so far as yet.
The purpose of this invention is to provide a kind of Naomaitong injection for cerebral angiopathy, single to solve existing treatment brain swift pulse medicine purposes, curative effect is low, the cycle is long, poison pays effect big problem, for brain swift pulse patient provides a kind of comprehensive therapeutic effect high new drug.
The object of the present invention is achieved like this: this injection contains Radix Salviae Miltiorrhizae, troxerutin, citicoline, coenzyme A, adenosine triphosphate, and is formulated through scientific technology, its proportioning following (weight portion)
Radix Salviae Miltiorrhizae 100-300 troxerutins 5-15
Citicoline 5-10 coenzyme As 1-2
Adenosine triphosphate 0.4 water 240-770
Its production technology comprises: select materials, be mixed, filtration, fill, sterilization, packing warehouse-in operation.
1, select materials:
A, Radix Salviae Miltiorrhizae are selected powder for use or are selected the Radix Salviae Miltiorrhizae water formulation for use;
B, troxerutin are selected powder for use or are selected the troxerutin water formulation for use;
C, citicoline are selected powder or citicoline water formulation for use;
D, coenzyme A are selected powder or coenzyme A water formulation for use;
E, adenosine triphosphate are selected powder or adenosine triphosphate water formulation for use;
2, be mixed:
Above-mentioned a, b, c, d, e powder are put into the container of belt stirrer in proportion, add 240-770 parts of distilled water then, stir and ended in 5-15 minutes;
3, filter:
Adopt filter centrifugal or filter to filter;
4, fill:
Adopt filling and sealing machine, every 20ml;
5, sterilization:
Adopt flowing steam sterilization, 100-150 ℃ of vapor (steam) temperatures, the time is more than 30 minutes;
6, packing warehouse-in:
Lucifuge, airtight, room temperature are preserved, storage life 3 years.
It is pale brown, clear and bright bright that this injection is, and do not have muddy, nothing precipitation.
Using method: the hemiplegia that cerebral thrombosis is caused, aphasia, dull-witted, apoplexy sequela, Menieres disease, the neurasthenia, quadriplegia, syndrome before the coronary heart disease infraction, hypertension, arteriosclerosis, thromboangiitis obliterans, thrombophlebitis, varicosis, diseases such as edema are effective in cure, but carotid artery injection, each 20ml is grown up, the next day once, five times is a course of treatment, 3-5 days can repeat to use by the course of treatment after the drug withdrawal, perhaps intravenous drip, and each 20ml is grown up, glucose injection 250-the 500ml that adds normal saline or 5-10%, once a day, 10 times is a course of treatment, and 3-5 days can repeat to use by the course of treatment after the drug withdrawal.
This medicine compared with prior art has the following advantages: 1) this product has the effect that suppresses erythrocyte and platelet aggregation, can prevent and treat thrombosis, and the content of oxygen in blood vessel dilating, the increase blood is arranged, and reduces blood viscosity; Can prevent and treat cerebral edema, promote neovascularity to generate, activate brain cell, the accelerator nerve functional rehabilitation; Can prevent and treat senile dementia, resisting radiation damage, anti-inflammatory effect are arranged, purposes is wide; 2) curative effect height reaches more than 94% according to 130 routine clinical practice statistics effective percentage, shortens a week than the other drug treatment cycle; 3) toxicity is low, does not find the effect of paying so far; 4) technology is simple, and is easy to use.
Illustrate below:
Example 1: No. 1, Naomaitong injection for cerebral angiopathy, its proportioning is as follows: (weight in grams)
Radix Salviae Miltiorrhizae 300 troxerutins 5
Citicoline 5 coenzyme As 1
Adenosine triphosphate 0.4 water 635
Compound method:
1, select materials: Radix Salviae Miltiorrhizae, troxerutin, citicoline, coenzyme A, adenosine triphosphate all adopt powder;
2, be mixed: pour above-mentioned powder into band in proportion respectively and stir in the container of device, adding distil water 635 grams stirred 10 minutes then;
3), filter: adopt filter to filter;
4), fill: use the filling and sealing machine filling and sealing, every 20ml;
5), sterilization: adopt flowing steam sterilization, temperature is 110 ℃, 30 minutes time;
This medicine is suitable for the carotid artery injection, and the hemiplegia aphasia that cerebral thrombosis is caused has specially good effect, if production lot can increase greatly in proportion.
No. 2, example 2, Naomaitong injection for cerebral angiopathy, its proportioning is as follows: (weight in grams)
Radix Salviae Miltiorrhizae 100 troxerutins 15
Citicoline 10 coenzyme As 2
Adenosine triphosphate 0.4 water 265
Compound method is with example 1.
This medicine is suitable for intravenous drip, to reducing blood viscosity specially good effect is arranged.
Claims (5)
1, a kind of Naomaitong injection for cerebral angiopathy contains Radix Salviae Miltiorrhizae, troxerutin, citicoline, coenzyme A, adenosine triphosphate composition, and it is characterized in that: weight proportion is as follows: part
Radix Salviae Miltiorrhizae 100-300 troxerutins 5-15
Citicoline 5-10 coenzyme As 1-2
Adenosine triphosphate 0.4 water 240-770
2, injection according to claim 1 is characterized in that: No. 1 its best proportioning of Naomaitong injection for cerebral angiopathy is as follows: (weight in grams)
Radix Salviae Miltiorrhizae 300 troxerutins 5
Citicoline 5 coenzyme As 1
Adenosine triphosphate 0.4 water 635
3, according to the described injection of claim l, it is characterized in that: No. 2 best proportionings of Naomaitong injection for cerebral angiopathy are as follows: (weight in grams)
Radix Salviae Miltiorrhizae 100 troxerutins 15
Citicoline 10 coenzyme As 2
Adenosine triphosphate 0.4 water 265
4, injection according to claim 1, its production technology is characterised in that and comprises: selects materials, is mixed, filtration, fill, sterilization, packaging process, flowing steam sterilization is adopted in sterilization, and vapor (steam) temperature is 100-150 ℃, and the time is more than 30 minutes.
5, its use characteristic of injection according to claim 1 is: the hemiplegia that cerebral thrombosis is caused, aphasia, dull-witted, apoplexy sequela, Menieres disease, the neurasthenia, quadriplegia, syndrome before the coronary heart disease infraction, hypertension, arteriosclerosis, thromboangiitis obliterans, thrombophlebitis, varicosis, diseases such as edema are effective in cure, but carotid artery injection, each 20ml is grown up, the next day once, five times is a course of treatment, 3-5 days can repeat to use by the course of treatment after the drug withdrawal, perhaps intravenous drip, each 20ml is grown up, glucose injection 250-the 500ml that adds normal saline or 5-10%, once a day, 10 times is a course of treatment, can heavily use by the course of treatment in 3-5 days after the drug withdrawal, effective percentage is more than 94%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 95109431 CN1122241A (en) | 1995-09-18 | 1995-09-18 | Naomaitong injection for cerebral angiopathy |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 95109431 CN1122241A (en) | 1995-09-18 | 1995-09-18 | Naomaitong injection for cerebral angiopathy |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1122241A true CN1122241A (en) | 1996-05-15 |
Family
ID=5077209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 95109431 Pending CN1122241A (en) | 1995-09-18 | 1995-09-18 | Naomaitong injection for cerebral angiopathy |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1122241A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067586C (en) * | 1998-11-20 | 2001-06-27 | 李国荣 | Composite medicinal injection for hemiparalysis |
WO2001068064A3 (en) * | 2000-03-14 | 2002-01-17 | Ferrer Int | Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
WO2006056759A1 (en) * | 2004-11-24 | 2006-06-01 | The University Of Nottingham | Modulation of blood clotting |
CN100400051C (en) * | 2004-12-15 | 2008-07-09 | 阿尔贝拉医药控股(通化)有限公司 | Medicinal composition, and its preparing method and use |
CN103520190A (en) * | 2013-09-29 | 2014-01-22 | 陈铭 | High-energy substance for preventing and treating neurodegenerative disease of old people and medical application of substance |
CN108096303A (en) * | 2017-12-07 | 2018-06-01 | 王显明 | A kind of quick-acting combination medicines for being used to treat hemiplegia and/or paraplegia |
-
1995
- 1995-09-18 CN CN 95109431 patent/CN1122241A/en active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1067586C (en) * | 1998-11-20 | 2001-06-27 | 李国荣 | Composite medicinal injection for hemiparalysis |
WO2001068064A3 (en) * | 2000-03-14 | 2002-01-17 | Ferrer Int | Use of cdp-choline for the prophylactic treatment of cerebral ischemia |
US6930096B2 (en) | 2000-03-14 | 2005-08-16 | Ferrer Internacional, S.A. | Use of CDP-choline for the prophylactic treatment of cerebral ischemia |
CZ300616B6 (en) * | 2000-03-14 | 2009-07-01 | Ferrer Internacional, S. A. | Pharmaceutical composition |
US7635691B2 (en) | 2000-03-14 | 2009-12-22 | Ferrer Internacional, S.A. | Use of CDP-choline for the prophylactic treatment of cerebral ischemia |
WO2006056759A1 (en) * | 2004-11-24 | 2006-06-01 | The University Of Nottingham | Modulation of blood clotting |
CN100400051C (en) * | 2004-12-15 | 2008-07-09 | 阿尔贝拉医药控股(通化)有限公司 | Medicinal composition, and its preparing method and use |
CN103520190A (en) * | 2013-09-29 | 2014-01-22 | 陈铭 | High-energy substance for preventing and treating neurodegenerative disease of old people and medical application of substance |
CN108096303A (en) * | 2017-12-07 | 2018-06-01 | 王显明 | A kind of quick-acting combination medicines for being used to treat hemiplegia and/or paraplegia |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60212786T2 (en) | Use of polyunsaturated fatty acids for the primary prevention of cardiovascular events | |
EP0332918B1 (en) | Compositions containing a calcium antagonist and a lipid-lowering agent | |
CH680789A5 (en) | ||
JP2015503590A5 (en) | ||
DE60117046T2 (en) | COMBINATION OF FENOFIBRATE AND COENZYME Q10 FOR THE TREATMENT OF ENDOTHELIAL MISSING FUNCTION | |
EP0071357B1 (en) | Pharmaceutical and dietary composition when used for enhancement of 1-series pg production | |
CN1122241A (en) | Naomaitong injection for cerebral angiopathy | |
US5324748A (en) | Method for enhancement of 1-series PG production | |
RU2020114750A (en) | DOSAGE SCHEME OF SIPONIMODE | |
Minehan et al. | The interaction of etoposide with radiation: variation in cytotoxicity with the sequence of treatment | |
Beg et al. | Effect of 3-hydroxy-3-methylglutaric acid on blood lipids in normal and cholesterol-fed rats | |
DE4127469A1 (en) | Compsn. contg. chemotherapeutic agent and lithium salt - for treatment of bacterial or viral infection e.g. HSV and HIV, malaria, leishmaniasis, trypanosoma infection and Candida albicans | |
DE60211938T2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF METFORMIN AND A 4-OXOBUTANO ACID AND THEIR USE FOR THE TREATMENT OF DIABETES | |
Salerno et al. | Treatment of vasospastic angina pectoris at rest with nitroglycerin ointment: A short-term controlled study in the coronary care unit | |
CN1079243C (en) | Naoxinkang preparation and its producing technology | |
CN1593478A (en) | Medicinal powder for treating beriberi | |
WO1992020361A1 (en) | New combination of factor viii and an antifibrinolytic | |
Hintze et al. | Mechanisms of reflex bradycardia and hypotension by metabolites of arachidonic acid in the cat. | |
CN1562147A (en) | Radix scutellariae extract freeze-dried powder injection and its preparing method | |
CN1117848A (en) | Application of "Wujinshi" (a Chinese medicine) effective component in medicines with invigerating blood-circulation and regulating cell function | |
DE19616581C2 (en) | Use of oxaceprol to treat reperfusion damage | |
Kato et al. | Influence of 13-cis retinoic acid on zymosan-induced chemiluminescence of granulocytes | |
CN1682715A (en) | Anti-anoxia medicinal composition | |
CN1250236C (en) | Application of levant cotton in medicine | |
CN1053817C (en) | Acanthopanax root injection freeze-dried powder injection and producing technology for acanthopanax root extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C01 | Deemed withdrawal of patent application (patent law 1993) |